Vyriad closed a $25 million final tranche in its Series B, taking the round to $85 million to support first‑in‑human testing of VV‑169, an in vivo CAR‑T candidate for relapsed or refractory multiple myeloma. The financing targets translation of a viral‑vector platform to a clinical setting without the ex vivo manufacturing complexity of conventional CAR‑T. Investors and the company stressed that in vivo CAR‑T approaches could simplify production and broaden patient access if safety and efficacy are confirmed in humans. The tranche gives Vyriad runway for IND‑enabling work and an initial clinical campaign.